{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:55:51Z","timestamp":1787165751461,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s12325-023-02475-4","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T11:43:05Z","timestamp":1680522185000},"page":"2439-2456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase\u00a03 Clinical Trials"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-5830","authenticated-orcid":false,"given":"Arthur","family":"Kavanaugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warner","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9825-003X","authenticated-orcid":false,"given":"Kristen","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6005-3938","authenticated-orcid":false,"given":"May","family":"Shawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-2029","authenticated-orcid":false,"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"2475_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","volume":"14","author":"J Feld","year":"2018","unstructured":"Feld J, Chandran V, Haroon N, Inman R, Gladman D. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol. 2018;14:363\u201371.","journal-title":"Nat Rev Rheumatol"},{"key":"2475_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2020.05.089","volume":"84","author":"AB Gottlieb","year":"2021","unstructured":"Gottlieb AB, Merola JF. Axial psoriatic arthritis: an update for dermatologists. J Am Acad Dermatol. 2021;84:92\u2013101.","journal-title":"J Am Acad Dermatol"},{"key":"2475_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/bmj.38954.689583.DE","volume":"333","author":"CM McVeigh","year":"2006","unstructured":"McVeigh CM, Cairns AP. Diagnosis and management of ankylosing spondylitis. BMJ. 2006;333:581\u20135.","journal-title":"BMJ"},{"key":"2475_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361\u20138.","journal-title":"Arthritis Rheum"},{"key":"2475_CR5","doi-asserted-by":"publisher","first-page":"E715","DOI":"10.1016\/S2665-9913(21)00105-3","volume":"3","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase\u00a03 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021;3:E715\u201323.","journal-title":"Lancet Rheumatol"},{"key":"2475_CR6","doi-asserted-by":"crossref","unstructured":"Mease P, Helliwell PS, Gladman D, et al. Effect of guselkumab (TREMFYA\u00ae), a selective IL-23p19 inhibitor, on axial-related endpoints in patients with active PsA: results from a phase 3, randomized, double-blind, placebo-controlled study through 2 years [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https:\/\/acrabstracts.org\/abstract\/effect-of-guselkumab-tremfya-a-selective-il-23p19-inhibitor-on-axial-related-endpoints-in-patients-with-active-psa-results-from-a-phase-3-randomized-double-blind-placebo-controlled-study\/.","DOI":"10.1136\/annrheumdis-2022-eular.1691"},{"key":"2475_CR7","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12\/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase\u00a03, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73:1000\u20136.","journal-title":"Ann Rheum Dis"},{"key":"2475_CR8","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/acr.22645","volume":"67","author":"A Kavanaugh","year":"2015","unstructured":"Kavanaugh A, Puig L, Gottlieb AB, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res (Hoboken). 2015;67:1739\u201349.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2475_CR9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase\u00a03, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780\u20139.","journal-title":"Lancet"},{"key":"2475_CR10","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","volume":"75","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Puig L, Gottlieb AB, et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2). Ann Rheum Dis. 2016;75:1984\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2475_CR11","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73:817\u201323.","journal-title":"Ann Rheum Dis"},{"key":"2475_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71:258\u201370.","journal-title":"Arthritis Rheumatol"},{"key":"2475_CR13","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten D, Ostergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase\u00a02 study. Ann Rheum Dis. 2018;77:1295\u2013302.","journal-title":"Ann Rheum Dis"},{"key":"2475_CR14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase\u00a03 trial. Lancet. 2020;395:1115\u201325.","journal-title":"Lancet"},{"key":"2475_CR15","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase\u00a03 trial. Lancet. 2020;395:1126\u201336.","journal-title":"Lancet"},{"key":"2475_CR16","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol"},{"key":"2475_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40257-020-00585-1","volume":"22","author":"YW Huang","year":"2021","unstructured":"Huang YW, Tsai TF. HLA-Cw1 and psoriasis. Am J Clin Dermatol. 2021;22:339\u201347.","journal-title":"Am J Clin Dermatol"},{"key":"2475_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13073-017-0473-6","volume":"9","author":"ML Buchkovich","year":"2017","unstructured":"Buchkovich ML, Brown CC, Robasky K, et al. HLAProfiler utilizes k-mer profiles to improve HLA calling accuracy for rare and common alleles in RNA-seq data. Genome Med. 2017;9:86.","journal-title":"Genome Med"},{"key":"2475_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12079-015-0302-x","volume":"10","author":"R Verma","year":"2016","unstructured":"Verma R, Balakrishnan L, Sharma K, et al. A network map of interleukin-10 signaling pathway. J Cell Commun Signal. 2016;10:61\u20137.","journal-title":"J Cell Commun Signal"},{"key":"2475_CR20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218.","journal-title":"Genome Biol"},{"key":"2475_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7.","journal-title":"BMC Bioinform"},{"key":"2475_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.479","author":"S Siebert","year":"2021","unstructured":"Siebert S, Sweet KM, Ritchlin CT, et al. Guselkumab treatment modulates core psoriatic arthritis gene expression in two phase\u00a03 clinical trials (DISCOVER-1 and -2). Ann Rheum Dis. 2021. https:\/\/doi.org\/10.1136\/annrheumdis-2021-eular.479.","journal-title":"Ann Rheum Dis"},{"key":"2475_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.4172\/2155-9899.1000400","volume":"7","author":"B Guo","year":"2016","unstructured":"Guo B. IL-10 modulates Th17 pathogenicity during autoimmune diseases. J Clin Cell Immunol. 2016;7:400.","journal-title":"J Clin Cell Immunol"},{"key":"2475_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.671976","volume":"12","author":"MS Chimenti","year":"2021","unstructured":"Chimenti MS, Perricone C, D\u2019Antonio A, et al. Genetics, epigenetics, and gender impact in axial-spondyloarthritis susceptibility: an update on genetic polymorphisms and their sex related associations. Front Genet. 2021;12: 671976.","journal-title":"Front Genet"},{"key":"2475_CR25","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1136\/annrheumdis-2012-202922","volume":"72","author":"P Machado","year":"2013","unstructured":"Machado P, Landewe R, Braun J, et al. Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. Ann Rheum Dis. 2013;72:1104\u20137.","journal-title":"Ann Rheum Dis"},{"key":"2475_CR26","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/rheumatology\/kez457","volume":"59","author":"J Feld","year":"2020","unstructured":"Feld J, Ye JY, Chandran V, et al. Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis? Rheumatology (Oxford). 2020;59:1340\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"2475_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/BOR.0000000000000136","volume":"27","author":"L Eder","year":"2015","unstructured":"Eder L, Chandran V, Gladman DD. What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis? Curr Opin Rheumatol. 2015;27:91\u20138.","journal-title":"Curr Opin Rheumatol"},{"key":"2475_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/annrheumdis-2018-213779","volume":"78","author":"JD Reveille","year":"2019","unstructured":"Reveille JD, Zhou X, Lee M, et al. HLA class\u00a0I and II alleles in susceptibility to ankylosing spondylitis. Ann Rheum Dis. 2019;78:66\u201373.","journal-title":"Ann Rheum Dis"},{"key":"2475_CR29","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534\u201348.","journal-title":"N Engl J Med"},{"key":"2475_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","volume":"80","author":"X Baraliakos","year":"2021","unstructured":"Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase\u00a03 MAXIMISE trial. Ann Rheum Dis. 2021;80:582\u201390.","journal-title":"Ann Rheum Dis"},{"key":"2475_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614255","volume":"12","author":"D McGonagle","year":"2021","unstructured":"McGonagle D, Watad A, Sharif K, Bridgewood C. Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis. Front Immunol. 2021;12: 614255.","journal-title":"Front Immunol"},{"key":"2475_CR32","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3389\/fimmu.2017.00920","volume":"8","author":"MN van Tok","year":"2017","unstructured":"van Tok MN, Satumtira N, Dorris M, et al. Innate immune activation can trigger experimental spondyloarthritis in HLA-B27\/Hubeta2m transgenic rats. Front Immunol. 2017;8:920.","journal-title":"Front Immunol"},{"key":"2475_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3109\/03009742.2014.956142","volume":"44","author":"SH Sveaas","year":"2015","unstructured":"Sveaas SH, Berg IJ, Provan SA, et al. Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study. Scand J Rheumatol. 2015;44:118\u201324.","journal-title":"Scand J Rheumatol"},{"key":"2475_CR34","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/art.24568","volume":"60","author":"H Shen","year":"2009","unstructured":"Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60:1647\u201356.","journal-title":"Arthritis Rheum"},{"key":"2475_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jcma.2012.05.006","volume":"75","author":"WS Chen","year":"2012","unstructured":"Chen WS, Chang YS, Lin KC, et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J Chin Med Assoc. 2012;75:303\u20138.","journal-title":"J Chin Med Assoc"},{"key":"2475_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.5114\/ceji.2019.92805","volume":"44","author":"H Deveci","year":"2019","unstructured":"Deveci H, Turk AC, Ozmen ZC, Demir AK, Say Coskun SU. Biological and genetic evaluation of IL-23\/IL-17 pathway in ankylosing spondylitis patients. Cent Eur J Immunol. 2019;44:433\u20139.","journal-title":"Cent Eur J Immunol"},{"key":"2475_CR37","doi-asserted-by":"publisher","first-page":"R569","DOI":"10.1186\/ar1698","volume":"7","author":"E Kruithof","year":"2005","unstructured":"Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther. 2005;7:R569\u201380.","journal-title":"Arthritis Res Ther"},{"key":"2475_CR38","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.4049\/jimmunol.181.8.5183","volume":"181","author":"S von Vietinghoff","year":"2008","unstructured":"von Vietinghoff S, Ley K. Homeostatic regulation of blood neutrophil counts. J Immunol. 2008;181:5183\u20138.","journal-title":"J Immunol"},{"key":"2475_CR39","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","volume":"13","author":"E Suzuki","year":"2014","unstructured":"Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23\/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13:496\u2013502.","journal-title":"Autoimmun Rev"},{"key":"2475_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-94-024-0921-5_5","volume":"941","author":"S Rutz","year":"2016","unstructured":"Rutz S, Ouyang W. Regulation of interleukin-10 expression. Adv Exp Med Biol. 2016;941:89\u2013116.","journal-title":"Adv Exp Med Biol"},{"key":"2475_CR41","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190418","volume":"217","author":"M Saraiva","year":"2020","unstructured":"Saraiva M, Vieira P, O\u2019Garra A. Biology and therapeutic potential of interleukin-10. J Exp Med. 2020;217:e20190418.","journal-title":"J Exp Med"},{"key":"2475_CR42","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1084\/jem.194.4.519","volume":"194","author":"P Ye","year":"2001","unstructured":"Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194:519\u201327.","journal-title":"J Exp Med"},{"key":"2475_CR43","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55:379\u201390.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2475_CR44","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/jcla.21768","volume":"29","author":"F Gokmen","year":"2015","unstructured":"Gokmen F, Akbal A, Resorlu H, et al. Neutrophil-lymphocyte ratio connected to treatment options and inflammation markers of ankylosing spondylitis. J Clin Lab Anal. 2015;29:294\u20138.","journal-title":"J Clin Lab Anal"},{"key":"2475_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s42358-020-0113-5","volume":"60","author":"MH Al-Osami","year":"2020","unstructured":"Al-Osami MH, Awadh NI, Khalid KB, Awadh AI. Neutrophil\/lymphocyte and platelet\/lymphocyte ratios as potential markers of disease activity in patients with ankylosing spondylitis: a case-control study. Adv Rheumatol. 2020;60:13.","journal-title":"Adv Rheumatol"},{"key":"2475_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/1346-8138.13061","volume":"43","author":"DS Kim","year":"2016","unstructured":"Kim DS, Shin D, Lee MS, et al. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol. 2016;43:305\u201310.","journal-title":"J Dermatol"},{"key":"2475_CR47","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1186\/s13063-022-06589-y","volume":"23","author":"DD Gladman","year":"2022","unstructured":"Gladman DD, Mease PJ, Bird P, et al. Efficacy and safety of guselkumab in biologic-na\u00efve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials. 2022;23:743.","journal-title":"Trials."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02475-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02475-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02475-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T15:16:17Z","timestamp":1682435777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02475-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2475"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02475-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}